Treatment Clinical Trials for Adrenocortical Carcinoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for adrenocortical carcinoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-11 of 11
  • Nivolumab and Ipilimumab in Treating Patients with Rare Tumors

    This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 733 locations

  • Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

    This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.
    Location: 100 locations

  • Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

    This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric / GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric / gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .
    Location: 11 locations

  • A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

    This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-176 for participants with advanced solid tumors likely to express Prolactin Receptor (PRLR). The study will consist of 2 cohorts: Dose Escalation and Expanded Recommended Phase 2 Dose.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Cytoreductive Surgery and Heated Cisplatin in Treating Patients with Adrenocortical Cancer

    This phase II trial studies how well cytoreductive surgery and heated cisplatin in treating patients with adrenocortical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving heated cisplatin directly into the abdomen after cytoreductive surgery may prevent or increase the length of time that it takes for the tumors to grow back.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Pembrolizumab in Treating Patients with Rare Tumors That Cannot Be Removed by Surgery or are Metastatic

    This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pembrolizumab in Treating Patients with Advanced Adrenocortical Cancer That Cannot Be Removed by Surgery

    This phase II trial studies how well pembrolizumab works in treating patients with adrenocortical cancer that cannot be removed by surgery or has spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and may block tumor growth in different ways by targeting certain cells.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies

    This randomized phase I / II trial studies the side effects and best dose of hypofractionated stereotactic body radiation therapy when given together with ipilimumab in treating patients with solid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as ipilimumab, may block tumor growth in different ways by targeting certain cells. Hypofractionated radiation is a radiation treatment in which the total dose of radiation is divided into large doses and treatments are given over a shorter period of time. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving ipilimumab with hypofractionated stereotactic body radiation therapy may be a better treatment for advanced solid malignancies.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum

    This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody 8H9 in treating patients with small round cell tumors that cause or form adhesions or fibrous connective tissue within a tumor (desmoplastic) and other solid tumors involving the peritoneum. Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 8H9, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • Efficacy of Adjuvant Mitotane Treatment (ADIUVO)

    Study Rationale Adrenocortical carcinoma (ACC) is a very rare disease with a high risk of relapse after radical surgery. The efficacy of adjuvant mitotane treatment is suggested by a retrospective multicenter international study showing that postoperative mitotane treatment was associated with a significant reduction of the risk of relapse and death. However, these promising results need confirmation in a randomized prospective study. Caution should be adopted particularly in patients with low risk of disease relapse, in whom the benefit of therapy should be weighted against the side effects. Even if an adjuvant treatment seems justified in patients at high risk of relapse, a randomised prospective study is needed to assess whether such a treatment is efficacious in patients at low-intermediate risk. The purpose of the present study is to determine whether adjuvant mitotane treatment is effective in prolonging the disease free survival in patients with adrenocortical carcinoma at low-intermediate risk of progression who underwent radical resection
    Location: See Clinical Trials.gov

  • Mifepristone in Treating Patients With Cancer

    The purpose of this compassionate use study is to see if mifepristone prevents worsening of patients' cancer. Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is commonly used for the termination of pregnancies. Mifepristone has not been approved by the Food and Drug Administration for use in the treatment of cancer. However, previous work has indicated that mifepristone may be useful due to how it works.
    Location: University of New Mexico Cancer Center, Albuquerque, New Mexico